One test could have prevented terminal prostate cancer, says patient
One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...
Pharmabiz4d
Androgen receptor non-canonical domain binding degrader for treatment of relapsed, refractory castration-resistant prostate cancer
Androgen receptor non-canonical domain binding degrader for treatment of relapsed, refractory castration-resistant prostate cancer: K. Sadasivan Pillai Wednesday, March 5, 2025, 0 ...
Nature18d
Androgen membrane receptor modulates muscle strength
Androgens exert their effects largely by binding to nuclear androgen receptors to regulate gene expression, but they can also bind to receptors in plasma membranes to rapidly induce cellular ...
UroToday8d
APCCC Diagnostics 2025: When to Assess Biology with a Re-Biopsy?
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and ...
CURE7d
First Patient Dosed With HLD-0915 for mCRPC in First-In-Human Trial
The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant ...
Targeted Oncology8d
ARANOTE Trial Aligns With Prior ARPI Plus ADT Studies in mHSPC
In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...
GlobalData on MSN10d
Eikon raises almost $351m to advance cancer candidates through the clinic
Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.